v3.25.4
Cover - USD ($)
12 Months Ended
Dec. 31, 2025
Mar. 06, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2025    
Current Fiscal Year End Date --12-31    
Entity File Number 001-42212    
Entity Registrant Name IMPACT BIOMEDICAL INC.    
Entity Central Index Key 0001834105    
Entity Tax Identification Number 85-3926944    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 1400 Broadfield Blvd.    
Entity Address, Address Line Two Suite 130    
Entity Address, City or Town Houston    
Entity Address, State or Province TX    
Entity Address, Postal Zip Code 77084    
City Area Code (281)    
Local Phone Number 415-6576    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 7,599,000
Entity Common Stock, Shares Outstanding   107,821,231  
Documents Incorporated by Reference [Text Block] None    
Document Financial Statement Error Correction [Flag] false    
Entity Listing, Par Value Per Share $ 0.001    
Auditor Firm ID 606    
Auditor Opinion [Text Block] We have audited the accompanying consolidated balance sheets of Impact Biomedical, Inc., and its subsidiaries (the “Company”) as of December 31, 2025 and 2024, and the related consolidated statements of operations, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.    
Auditor Name GRASSI & CO., CPAs, P.C.    
Auditor Location Jericho, New York